The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Assessing targeted therapies in early stage NSCLC
Targeted therapies have recently made numerous advances in the field of non-small cell lung cancer (NSCLC). Jay Lee, MD, University of California, Los Angeles, CA, comments on ongoing trials that assess targeted therapies in earlier stages of lung cancer. Upcoming trials include the Phase III NeoADAURA trial (NCT04351555) of neoadjuvant osimertinib as monotherapy or with chemotherapy in resectable EGFR-mutated NSCLC, and the Phase II Geometry-N trial (NCT04926831) of neoadjuvant capmatinib in NSCLC with MET exon 14 or amplification mutations. Dr Lee additionally emphasizes alternative targets including KRAS G12C in the neoadjuvant setting. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
